Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

heparin-induced thrombocytopenia (HAT) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

heparin-induced thrombocytopenia

MONDO:0018048

Also known as:HATHITheparin-associated thrombocytopenia

Find Clinical TrialsTrials

Overview

Heparin-induced thrombocytopenia (HIT) is a drug-induced, immune-mediated prothrombotic disorder associated with thrombocytopenia and venous and/or arterial thrombosis.

Treatments2 FDA approved

Clinical Trials2 registered · 1 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include very common findings: Thromboembolism, Autoimmune thrombocytopenia, and Hypercoagulability; and common findings: Deep venous thrombosis, Increased serum serotonin, Arterial thrombosis, and Venous thrombosis. 15 total HPO annotations.

Organ System	Phenotype Count	Example Features
Blood and immune system	3	Autoimmune thrombocytopenia, Disseminated intravascular coagulation, Abnormal onset of bleeding

Diagnosis

Biomarker and diagnostic research for heparin-induced thrombocytopenia has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for heparin-induced thrombocytopenia, including ARGATROBAN (ARGATROBAN, approved 2018) and BIVALIRUDIN (BIVALIRUDIN, approved 2019). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Phenotype severity distribution: 3 very common features, 4 common features.

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

2 clinical trials registered, 1 recruiting. Interventions under study include procedural interventions and biologic therapy. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.

238 publications have been identified in PubMed for heparin-induced thrombocytopenia. Research spans Case Report / Case Series (27%), Review / Meta-Analysis (24%), and Basic Science / Preclinical (14%).

Research Type	Count	% of Total
Patient case studies	57

Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 11:13 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:3325

GARD

Genetic and Rare Diseases Info Center

GARD:2650

Questions for Your Care Team

→What are the benefits and potential side effects of ARGATROBAN for managing heparin-induced thrombocytopenia?
→Are any of the 2 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Refluden	Lepirudin	Hoechst Marion Roussel	1997	2005	Designated (drug approved for other indication)
Iloprost solution for infusion	Iloprost solution for infusion	Berlex Laboratories, Inc.	1990	—	Withdrawn

Kisho

heparin-induced thrombocytopenia

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

heparin-induced thrombocytopenia

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications